Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in treatments, survival of patients remains poor. To define novel pathways that regulate susceptibility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant glioma cells, levels of different miRs are increased, and in particular, miR-30b/c and -21. We demonstrate that these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. T98G-sensitive cells treated with miR-21 or -30b/c become resistant to TRAIL. Furthermore, we demonstrate that miR-30b/c and miR-21 target respectively the 3 0 untranslated region of caspase-3 and TAp63 mRNAs, and that those proteins mediate some of the effects of miR-30 and -21 on TRAIL resistance, even in human glioblastoma primary cells and in lung cancer cells. In conclusion, we show that high expression levels of miR-21 and -30b/c are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets for TRAIL resistance in glioma.
INTRODUCTION
Glioblastomas are the most common primary tumors of the brain and are divided into four clinical grades on the basis of their histology and prognosis. 1 These tumors are highly invasive, very aggressive and are one of the most incurable forms of cancer in humans. 2 The treatment strategies for this disease have not changed appreciably for many years, and failure of treatment occurs in the majority of patients owing to the strong resistant phenotype. Therefore, the development of new therapeutic strategies is necessary for this type of cancer.
A novel interesting therapeutic approach is the reactivation of apoptosis using member of TNF (tumor necrosis factor)-family, of which the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) holds the greatest interest. Apoptosis is a particularly desirable treatment outcome, as it eradicates cancer cells without causing a major inflammatory response, which could provide unwanted survival signals. However, many cancers develop functional defects in the drug-induced apoptosis pathway, which may lead to constitutive or acquired resistance. To this end, alternative pathways, such as the one activated by death receptors including Fas/Apo-1, or DR4 (TRAIL-R1) and DR5 (TRAIL-R2), are being explored for cancer treatment. TRAIL is a relatively new member of the TNF family, known to induce apoptosis in a variety of cancers. 3 Treatment with TRAIL induces programmed cell death in a wide range of transformed cells, both in vivo and in vitro, without producing significant effects in normal cells. 3, 4 Therefore, recombinant TRAIL or monoclonal antibodies against its receptors (TRAIL-R1 and TRAIL-R2) are in phase II/III clinical trials for different kinds of tumors, either as a single agent or in combination with chemotherapy. 5, 6 However, a significant proportion of human cancer cells are resistant to TRAIL-induced apoptosis, and the mechanisms of sensitization seem to differ among cell types. Different studies relate resistance to TRAIL-induced cell death to downstream factors. It has been shown that downregulation of two antiapoptotic proteins such as PED (Phosphoprotein enriched in diabetes) or cellular-FLICE such as inhibitory protein (c-FLIP) can sensitize cells to TRAIL-induced apoptosis. [7] [8] [9] However the mechanism of TRAIL resistance is still largely unknown. miRs are a class of endogenous non-coding RNA of 19-24 nucleotides in length that has an important role in the negative regulation of gene expression blocking translation or directly cleaving the targeted mRNA. 10 miRs are involved in the pathogenesis of most cancers. 10 In the last few years, our understanding of the role of miRNA has expanded from the initially identified functions in the development of round worms to a highly expressed and ubiquitous regulators implicated in a wide array of critical processes, including proliferation, cell death and differentiation, metabolism and, importantly, tumorigenesis. 11 We have recently showed an important role of microRNAs in TRAIL sensitivity in non-small cell lung cancer (NSCLC). [12] [13] [14] In this study, to identify novel mechanisms implicated in TRAIL resistance in human glioma, we performed a genome-wide expression profiling of miRs in different cell lines. We found that miR-30b/c and -21 are markedly upregulated in TRAILresistant, and downregulated in TRAIL-sensitive glioma cells.
Our experiments indicate that miR-30b/c and -21 modulate TRAIL sensitivity in glioma cells mainly by modulating caspase-3 and TAp63 expression and TRAIL-induced caspase machinery.
RESULTS

Selection of TRAIL-sensitive vs TRAIL-resistant glioma cell lines
We analyzed TRAIL sensitivity of different human glioma cell lines. Cells were exposed to TRAIL at two different concentrations for 24 h and cell death was assessed using the MTT assay (Figure 1a ) or propidium iodide staining ( Figure 1b) . As shown in Figure 1 , we can distinguish two sets of cells: TB10, LN229, U251 and U87MG cells exhibited total or partial TRAIL resistance, whereas T98G and LN18 cells underwent TRAIL-induced cell death. miRs expression screening in TRAIL-resistant vs TRAIL-sensitive glioma cell lines To investigate the involvement of miRs in TRAIL resistance in glioblastoma cell lines, we analyzed the miRs expression profile in the most TRAIL-resistant glioma cells (TB10 and LN229) vs the TRAIL-sensitive cells (T98G and LN18). The analysis was performed with a microarray chip containing 1150 miR probes, including 326 human and 249 mouse miRs, spotted in duplicates. Data obtained indicated that seven miRs (miR-21, -30b, -30c, -181a, -181d, -146 and -125b) were significantly overexpressed in resistant glioma cells with at least 41.9-fold change (Table 1) . Quantitative realtime-polymerase chain reaction (qRT-PCR) validated the microarray analysis (data not shown).
Role of miRs in TRAIL resistance in glioma
To test the role of these overexpressed miRs in TRAIL sensitivity in glioma, we transfected T98G TRAIL-sensitive cells with miR-21, -30b, -30c, -181a, -146 and -125b. TRAIL sensitivity was evaluated by MTT assay, propidium iodide staining and colony assay. We obtained significant results only for miR-30b/c and miR-21 that were then extensively investigated. In fact, data obtained with MTT assay and FACS analysis showed that the overexpression of miR-30b/c and -21 was able to revert TRAIL sensitivity in T98G (Figures 2a and b) . Similar results were obtained in LN18 cells (Figures 2c and d) . This effect was not restricted to glioma, as miR-30 and miR-21 were able to exert an anti-apoptotic action also in non small cell lung cancer (NSCLC) (Supplementary Figure 3B) . We further evaluated TRAIL sensitivity by colony assay. T98G and LN18 cells were transfected with miR-scrambled, miR30b/c and miR-21 for 48 h and then were treated with 50 or 100 ng/ml of superKiller TRAIL for 24 h. Cells were grown for 6 days and then coloured with crystal violet-methanol solution (Supplementary Figures 1A and B) . The results indicated that both miRs induced an increase of TRAIL resistance.
To further explore the role of miR-21 and -30b/c on TRAIL sensitivity, we transfected U251 (Figure 3a) or LN229 (Figure 3b ) TRAIL-resistant cells with anti-miR-21, -30b, 30c, or with a scrambled sequence. As shown in Figures 3a and b , transfection of the anti-miR sequences was able to sensitize U251 and LN229 cells to TRAIL. Anti-miR-21 and -30c were also able to sensitize to TRAIL the CALU-1-resistant non-small cell lung cancer (NSCLC) TRAIL-resistant cell lines (Supplementary Figure 3C) , indicating that this effect was not restricted to glioma.
Identification of cellular targets of miR-30b/c and miR-21 in glioma cells To identify cellular targets of miR-30b/c and -21, we used as first attempt a bioinformatic search, using programs available on the web including Pictar, TargetScan, miRanda and Microcosm target. miR-21 targets different tumor suppressor genes and proteins potentially involved in TRAIL resistance in glioblastoma cells, such as PTEN (phosphatase and tensin homologue), PDCD4 (programmed cell death 4), TPM1 (Tropomyosin 1) and p53. [15] [16] [17] Computer-assisted analysis identified the presence of evolutionary-conserved binding sites for miR-21 in TAp63 gene. We focused our attention on this p53 family member, as it regulates the expression of TRAIL receptors and molecules involved in TRAIL signaling. 18 We also searched for miR-30 targets and among them we focused on caspase-3.
TRAIL-resistant and TRAIL-sensitive glioma or NSCLC cells exhibited different levels of miR-21 and -30c assessed by either qRT-PCR (Figure 4a and Supplementary Figure 3A) or by northern blot analysis (Supplementary Figure 4) . Interestingly, we observed a reduction of protein (Figure 4b and Supplementary Figure 3D ) and mRNA ( Figure 4c ) levels of TAp63 and caspase-3 upon, respectively, miR-21 or miR-30c and miR-30b (data not shown) transfection in TRAIL-sensitive cell lines. We didn't observe a Figure 5b ). Interestingly, transfection of TAp63 and caspase-3 was able to overcome the effects of miR-21 and miR-30c, decreasing cell viability and increasing apoptosis (Figures 5a and b) . The data were confirmed by colony assay in T98G cells ( Supplementary Figures 2A and B) . Similar results were obtained when we analyzed miR-30b (data not shown). These rescue experiments proved the causative link between miR-21/ TAp63 and caspase-3/miR-30b/c and TRAIL sensitivity.
Effect of miR-21 and miR-30c expression on TRAIL sensitivity in primary human glioma cell lines MiR-21 and miR-30c expression levels were measured by qRT-PCR in nine different human primary cell lines (Figure 6a ), eight derived from glioblastoma tumors (patient no. 1 to no. 8) and one from tissue surrounding the tumor (patient no. 9), and compared with TRAIL sensitivity. As shown in Figure 6b , TRAIL sensitivity correlated with miR-21 and miR-30c expression levels in all cases analyzed, with the exception of control sample that did not respond to TRAIL. Moreover, anti-miRs expression in TRAIL- resistant primary cultured cells (patient no. 1 and no. 2) was able to determine an increase of TRAIL sensitivity (Figure 6c ) and concomitantly an increase of the levels of TAp63 and caspase-3 ( Figure 6d ).
DISCUSSION
Sensitization of cancer cells to apoptosis could be a valuable strategy to define new treatment options for cancer, in particular when using agents that aim to directly activate apoptotic pathways. A promising agent is the death receptor ligand TRAIL, 19 as it induces apoptosis in most cancer cells, but not in normal cells. 20, 21 Moreover, TRAIL exhibits potent tumoricidal activity in vivo in several xenograft models, including malignant glioma. 22, 23 Indeed, agonistic anti-TRAIL receptor monoclonal antibodies (mAbs), including mapatumumab (HGS-ETR1, antihuman DR4 mAb), 24 lexatumumab (HGS-ETR2, anti-human DR5 mAb) 25 and MD5-1 (anti-mouse DR5 mAb) are currently under intensive investigation. The former two mAbs have been tested in phase 1 clinical trials in patients with systemic malignancy, exhibiting excellent safety profiles. Anti-mouse DR5 mAb MD5-1 could also be administered safely without inducing hepatotoxicity either alone or in combination with histone deacetylase inhibitors in mice. 26 The induction of apoptosis by TRAIL is essentially dependent on the expression of specific TRAIL receptors and on the activation of caspases, 20 thus the regulation of the expression levels of those molecules is of fundamental importance.
MicroRNAs are emerging as key regulators of multiple pathways involved in cancer development and progression, [27] [28] [29] and may become the next targeted therapy in glioma. The present study shows that microRNA expression may modulate TRAIL-induced apoptosis in glioma cells, by the regulation of caspase-3 and TAp63 levels. We analyzed the miRs profile of TRAIL-resistant compared with TRAIL-sensitive glioma cells. We then focused our attention on miR-30b/c and miR-21, as only these miRs among those identified by the array, demonstrated the ability to revert the TRAIL-sensitive phenotype. We also provided evidences that this regulation is not restricted to glioma, but it is present also in a different type of cancer such as NSCLC.
MiR-21 has been found overexpressed in high-grade glioma patients 30 and studies have identified different miR-21 key targets for glioma biology, such as RECK, TIMP3, Spry2 and Pdcd4 genes, which are suppressors of malignancy and inhibitors of matrix metalloproteinase. 16, [31] [32] [33] Moreover, levels of expression of miR-21 have been associated to patients survival. 34 Other studies indicate that knockdown of miR-21 in cultured glioblastoma cells triggers activation of caspases and leads to increased apoptotic cell death. 35 Corsten et al. 36 hypothesized that suppression of miR-21 might sensitize gliomas for cytotoxic tumor therapy. With the use of locked nucleic acid (LNA)-anti-miR-21 oligonucleotides and neural precursor cells (NPC) expressing a secretable variant of TRAIL (S-TRAIL), they showed that the combined suppression of miR-21 and NPC-S-TRAIL leads to a synergistic increase in caspase activity and a decreased cell viability in human glioma cells in vitro and in vivo in xenograft experiments. Interestingly, Papagiannakopoulos et al. 15 described that miR-21 targets multiple important components of the p53 tumor-suppressive pathways. They showed that downregulation of miR-21 in glioblastoma cells leads to repression of growth, increased apoptosis and cell cycle arrest, through the regulation of target proteins such as HNRPK and TAp63. Our study describes for the first time the direct link between miR-21, TAp63 and TRAIL sensitivity. We demonstrated that miR-21 targets the 3 0 UTR sequence of TAp63, and that transfection of miR-21 is able to downregulate TAp63 at both mRNA and protein levels. More importantly, we demonstrated that miR-21, through TAp63, is able to modulate TRAIL sensitivity, as the co-transfection of miR-21 and TAp63 cDNA renders the cells again responsive to TRAIL. TAp63 is a transcription factor that regulates the expression levels of different apoptosis-regulating genes, such as TRAIL receptors, bcl2l11 and Apaf1. 18 Thus, it is possible that those apoptosisregulating molecules are regulated by miR-21 through TAp63.
Several studies link miR-30 to apoptosis and human cancer. Li et al. 37 demonstrated that miR-30 family members inhibited mitochondrial fission through the suppression of the expression of p53 and its downstream target Drp1, whereas, Joglekar et al. 38 demonstrated that miR-30 may have a role in epithelial-tomesenchymal transition. Our recent data demonstrate that miR-30 targets the anti-apoptotic protein BIM, participating to gefitinib resistance in lung cancer. 39 MiR-30 has been also associated with stem cell properties. Yu et al. 40 described that miR-30 is reduced in breast tumor stem cells (BT-ICs), and demonstrated that enforced expression of miR-30 in BT-ICs inhibits their self-renewal capacity by reducing Ubc9, and induces apoptosis through silencing ITGB3. In our hands, miR-30 overexpression inhibits TRAIL-induced apoptosis in glioma cells by targeting caspase-3. In fact, modulating the expression of either miR-30 or caspase-3, we observed a modification of TRAIL sensitivity of glioma cells. The opposing results on the role of miR-30 on cell death may be ascribed either to different cell system (breast vs glioma), or to different type of cancer cell (stem vs differentiated cells). In favour of this hypothesis, many reports describe opposing role of miRs in a different cell contest. 28 Recently, miR-30d has been described to target caspase-3 in breast cancer cells, and thus to regulate apoptosis. 41 The seed sequence recognizing the 3 0 UTR of caspase-3 is highly homologous within the members of the miR-30 family (miR-30b/c/d) suggesting a more generalized role of miR-30 family members in the regulation of cell death and cancer progression. In many experiments, we observed that there is a redundancy within miR-21 and miR-30 in the regulation of TRAIL sensitivity. Our data, either in primary or in established cell lines, demonstrates that it is sufficient that one of the two miRs is highly expressed in the cells, that apoptosis resistance will manifest. We have also observed that miR-30 has a predominant effect in contrasting TRAIL-induced apoptosis. This may be related to the effect of this miR in targeting one important component of the cell death machinery, that is, caspase-3.
In conclusion, our study analyzed microRNA expression pattern in TRAIL-resistant and TRAIL-sensitive glioma cells, and identified specific miRs and their targets involved in the regulation of the apoptotic programme. This may be of relevance for future cancer therapy improvement in glioma.
MATERIALS AND METHODS
Cell culture and transfection U87MG, T98G, U251, TB10, CALU-1 and 293 cells were grown in Dulbecco's modified Eagle's medium (DMEM). H460 were grown in RPMI. Media were supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine and 100 U/ml penicillin/streptomycin. LN229 and LN18 were grown in Advanced DMEM (Invitrogen, Milan Italy) þ 2 mM Glutamine þ 5% fetal bovine serum. For miRs transient transfection, cells at 50% confluency were transfected using Oligofectamine (Invitrogen) with 100 nM of pre-miR30c, -30b, -125b, -146b, -181a, -21, miR-scrambled or anti-miR-(Applied Biosystems, Milan, Italy). For caspase-3 and TAp63 transient transfection, cells were transfected using Lipofectamine and Plus Reagent with 4 mg of caspase-3 cDNA (Origene, Rockville, MD, USA) or TAp63 cDNA for 24 h. TAp63 cDNA was obtained from Professor Viola Calabrò (Naples). SuperKiller TRAIL for cell treatment was purchased from Enzo Biochem (New York, NY, USA).
Primary cell cultures
Glioblastoma specimens were collected at neurosurgical Unit of Cardarelli hospital (Naples). All the samples were collected according to a prior consent of the donor before the collection, acquisition or use of human tissue. To obtain the cells, samples were mechanically disaggregated, then the lysates were grown in DMEM-F12 medium supplemented with 10% fetal bovine serum 1% penicillin streptomicyn and 20 ng/ml EGF (SigmaAldrich, Milan, Italy). To exclude a fibroblast contamination, cells were stained for GFAP, a protein found in glial cells.
Protein isolation and western blotting
Cells were washed twice in ice-cold phosphate-buffered saline, and lysed in JS buffer (50 mM HEPES pH 7.5 containing 150 mM NaCl, 1% Glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 5 mM EGTA, 1 mM Na 3 VO 4 and 1 Â protease inhibitor cocktail). Protein concentration was determined by the Bradford assay (Bio-Rad, Milan, Italy) using bovine serum albumin as the standard, and equal amounts of proteins were analyzed by SDS-PAGE (12.5% acrylamide). Gels were electroblotted onto nitrocellulose membranes (Millipore, Bedford, MA, USA). For immunoblot experiments, membranes were blocked for 1 h with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20, and incubated at 4 1C over night with primary antibody. Detection was performed by peroxidase-conjugated secondary antibodies using the enhanced chemiluminescence system (GE Healthcare, Milan, Italy). Primary antibodies used were: anti-bActin from Sigma-Alrich; anti-caspase-8, 9 and 10 were from Cell Signalling Technology (Boston, MA, USA); anti-Caspase 3 and anti-TAp63 from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
miRNA microarray experiments
From each sample, 5 mg of total RNA (from T98G, LN18, TB10, LN229 cells) was reverse transcribed using biotin-end-labelled random-octamer oligonucleotide primer. Hybridization of biotin-labelled cDNA was performed on an Ohio State University custom miRNA microarray chip (OSU_CCC version 3.0), which contains 1150 miRNA probes, including 326 human and 249 mouse miRNA genes, spotted in duplicates. The hybridized chips were washed and processed to detect biotin-containing transcripts by streptavidin-Alexa647 conjugate and scanned on an Axon 4000B microarray scanner (Axon Instruments, Sunnyvale, CA, USA).
Raw data were normalized and analyzed with GENESPRING 7,2 software (zcomSilicon Genetics, Redwood City, CA, USA). Expression data were median-centered by using both the GENESPRING normalization option and the global median normalization of the BIOCONDUCTOR package (www.bioconductor.org) with similar results. Statistical comparisons were done by using the GENESPRING ANOVA tool, predictive analysis of microarray and the significance analysis of microarray software (http:// www-stat.stanford.edu/Btibs/SAM/index.html).
RNA extraction and real-time PCR
Total RNAs (miRNA and mRNA) were extracted using Trizol (Invitrogen) according to the manufacturer's protocol. Reverse transcription of total miRNA was performed starting from equal amounts of total RNA per sample (1 mg) using miScript reverse Transcription Kit (Qiagen, Milan, Italy), for mRNASuperScript III Reverse Transcriptase (Invitrogen) was used. For cultured cells, quantitative analysis of Caspase-3, Tap63, b-Actin (as an internal reference), miR-30b/c, miR-21 and RNU5A (as an internal reference) were performed by real-time PCR using specific primers (Qiagen), miScript SYBR Green PCR Kit (Qiagen) and iQ SYBR Green Supermix (Bio-Rad), respectively. 0 . All reactions were run in triplicate. The threshold cycle (CT) is defined as the fractional cycle number at which the fluorescence passes the fixed threshold. For relative quantization, the 2 ( À DCT) method was used as previously described. 42 Experiments were carried out in triplicate for each data point, and data analysis was performed by using software (Bio-Rad).
Northern blot analysis RNA samples (30 mg) were separated by electrophoresis on 15% acrylamide, 7 mol/l urea gels (Bio-Rad, Hercules, CA, USA) and transferred onto Hybond-N þ membrane (Amersham Biosciences, Piscataway, NJ, USA). Hybridization was performed at 37 1C in 7% SDS/0.2 mol/l Na 2 PO 4 (pH 7.0) for 16 h. Membranes were washed at 42 1C, twice with 2 Â standard saline phosphate (0.18 mol/l NaCl/10 mmol/l phosphate (pH 7.4)), 1 mmol/l EDTA (saline-sodium phosphate-EDTA; SSPE) and 0.1% SDS and twice with 0.5 Â SSPE/0.1% SDS. The oligonucleotides (PRIMM, Milan, Italy) used, complementary to the sequences of the mature miRNAs, were: miR-21-probe 5 0 -TCAACATCAGTCTGATAAGCTA-3 0 ; miR-30c-probe 5 0 -GCTGAG AGTGTAGGATGTTTACA-3
0 . An oligonucleotide complementary to the U6 RNA (5 0 -GCAGGGGCCATGCTAATCTTCTCTGTATCG-3 0 ) was used to normalize the expression levels. Totally, 100 pmol of each probe were end labelled with 50 mCi [g-32P]ATP using the poly-nucleotide kinase (Roche, Basel, Switzerland). Blots were stripped by boiling in 0.1% SDS for 10 min before re-hybridization.
Luciferase assay The 3 0 UTR of the human Caspase-3 genes was PCR amplified using the following primers: Caspase-3 forward: 5 0 -TCTAGAAGGGCGCCATCGCCAAG TAAGAAA-3 0 , Caspase-3 reverse: 5 0 -TCTAGACCCGTGAAATGTCATACTGA CAG-3 0 and cloned downstream of the Renilla luciferase stop codon in pGL3 control vector (Promega, Milan, Italy). A deletion was introduced into the miRNA-binding sites by using the QuikChange Mutagenesis Kit (Stratagene, La Jolla, CA, USA) using the following: primers: Caspase-3 mut forward 5 0 -GCAAAATTCTTAAGTATGTTATTTTCTGTTGAAATCAAAGGA AAATAGTAATGTTTTATACT-3 0 . Caspase-3mut reverse 5 0 -AGTATAAAACAT TACTATTTTCCTTTGATTTCAACAGAAAATAACATACTTAAGAATTTTGC-3 0 . The 3 0 UTR of the human TAp63 gene was PCR amplified using the following primers: TAp63 forward: 5 0 -TCTAGAGCAAGAGATAAGTCTTT CATGGCTGCTG-3 0 , TAp63 reverse: 5 0 -TCTAGATGGAAATCCCACTATCCCA AG-3 0 , and cloned downstream of the Renilla luciferase stop codon in pGL3 control vector (Promega). A deletion was introduced into the miRNAbinding sites by using the QuikChange Mutagenesis Kit (Stratagene) using the following: primers:TAp63 mut forward 5 0 -CTGGTCAAGGGCTGTCATTG CACTCCATTTTAATTT-3 0 TAp63 mut reverse 5 0 -AAATTAAAATGGAGTGCAAT GACAGCCCTTGACCAG-3 0 . Hek-293 cells were cotransfected with 1.2 mg of generated plasmid and 400 mg of a Renilla luciferase expression construct pRL-TK (Promega) with Lipofectamine 2000 (Invitrogen). Cells were harvested 24 h post transfection and assayed with Dual Luciferase Assay (Promega) according to the manufacturer's instructions. Three independent experiments were performed in triplicate.
Cell death quantification
Cells were plated in 96-well plates in triplicate, stimulated and incubated at 37 1C in a 5% CO 2 incubator. SuperKiller TRAIL was used at final concentration of 50 or 100 ng/ml for 24 h. Apoptosis was analyzed via propidium iodide incorporation in permeabilized cells by flow cytometry. The cells (2 Â 10 5 ) were washed in phosphate-buffered saline and resuspended in 200 ml of a solution containing 0.1% sodium citrate, 0.1% Triton X-100 and 50 mg/ml propidium iodide (Sigma). Following incubation at 4 1C for 30 min in the dark, nuclei were analyzed with a Becton Dickinson FACScan flow cytometer (Becton Dickinson, Milan, Italy). Cellular debris was excluded from analyses by raising the forward scatter threshold, and the DNA content of the nuclei was registered on a logarithmic scale. The percentage of elements in the hypodiploid region was calculated. Cell viability was evaluated with the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer's protocol. Metabolically active cells were detected by adding 20 ml of MTS to each well. After 2 h of incubation, the plates were analyzed in a Multilabel Counter (BioTek, Milan, Italy).
Colony assay
Cells were transfected with miR-scrambled, miR-30b/c or miR-21 for 24 h, then were harvested and 2.4 Â 10 4 cells were plated in six-well plates. After 24 h, cells were treated with 50 or 100 ng/ml of superKiller TRAIL for 24 h, as indicated. Cells were transferred to 100 mm dishes and let grown for 6 days. Finally, the cells were coloured with 0.1% crystal violet dissolved in 25% methanol for 20 min at 4 1C. Dishes were washed with water and then let dry on the bench, and then photographs were taken.
